View Post

Eftilagimod Alpha/Paclitaxel Combo Shows Improved OS in Metastatic HR+ Breast Cancer Subsets

In In The News by Barbara Jacoby

By: Chris Ryan From: onclive.com The combination of eftilagimod alpha and paclitaxel produced a modest increase in median overall survival (OS) in patients with endocrine-resistant hormone receptor (HR)–positive/HER2-negative metastatic breast cancer; though, the effects were significant in patients younger than 65 years old, had low monocytes, or had more aggressive disease (luminal B), according to a post hoc analysis of …

View Post

Risk varies for breast cancer spreading to other body parts

In In The News by Barbara Jacoby

By: Amerigo Allegretto From: auntminnie.com The risk that a woman with early breast cancer will see it spread to another part of the body can be up to 22%, according to a global study presented at the Advanced Breast Cancer Sixth International Consensus Conference, being held November 4-6 in Lisbon. In her presentation, Eileen Morgan, PhD, from the World Health …